Post Stroke Spasticity Service Use of Botulinum Toxin A (980)

Warning

exp date isn't null, but text field is

Abstract

Spasticity is part of the upper motor neurone syndrome and is common in conditions affecting the brain and spinal cord such as cerebral palsy (CP), acquired brain injury (ABI), stroke (CVA), multiple sclerosis (MS), hereditary spastic paraparesis (HSP) and spinal cord injury (SCI). Botulinum toxin A is a recognised treatment for focal spasticity as well as dystonia. It may be required
to prevent loss of function, secondary complications, help manage pain or before rehabilitation goals can be met.

Resources

Use the button below to access this resource item.

Access this resource

Tags

Acute / All Inpatient

Last reviewed: 21 December 2021

Next review: 31 December 2023

Author(s): Niall Hughes

Version: 1

Author Email(s): [email protected]

Approved By: Medicines Utilisation Subcommittee of ADTC

Document Id: 980